Anthropic just posted numbers that made OpenAI's growth look slow, and now it wants a $2 trillion valuation at IPO. Whether that price tag reflects a genuine breakthrough or a dangerous case of AI…
SanDisk just posted one of the most violent stock runs in large-cap history, yet institutional investors are betting against each other in the options market with unusual aggression. The bull and bear cases point…
Daniel Sundheim built a position in SpaceX so large it dwarfs every other holding in D1 Capital's book, and the reason behind that concentration rewrites the usual story about what kind of company SpaceX…
Brad Gerstner just placed some of his biggest bets of the year during one of the choppiest quarters for tech stocks, and his picks reveal exactly where Altimeter Capital thinks the AI trade heads…
GM's relentless buyback machine crushed Ford and the S&P 500 for over a year, but something shifted in 2026 and now the tortoise is quietly pulling ahead. Before you bet on which automaker wins…
Most retirees scrambling to cover missed quarterly tax payments assume they have run out of options by December, but the IRS treats one common year-end transaction in a way that quietly rewrites the timeline…
A massive warrant disclosure just reshuffled who builds Google's AI chips, sending one semiconductor giant surging while punishing the longtime incumbent with a 3% drop before markets had time to blink.
Eli Lilly just became the first pharmaceutical company ever valued above $1 trillion, yet analysts who dig into its pipeline are arguing the market still has not grasped what the next two years could…
SK Hynix just approved the largest treasury share cancellation in South Korean stock market history, and the move is pulling the entire memory sector off its lows. The real question is whether record capital…
AI data centers are quietly reshaping who profits from the natural gas boom, and it has nothing to do with the drillers. Three pipeline ETFs with yields as high as 8 percent are sitting…
A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have finally crossed…
With volatility near a 12-month low, the premium that SPYI, JEPQ, and GPIQ convert into monthly cash has shrunk, and a $500,000 stake in the wrong fund now exposes a flaw most investors discover…
A seven-week trial against Meta carries a headline damages figure that most investors are anchoring to for the wrong reasons, and the part of the case that could actually reshape the apps barely makes…
Not all mortgage REITs offering double-digit yields are running the same play, and confusing one for another right now carries real consequences for income investors.
Home Depot's stock sits well below its 52-week high after a rough stretch, but something in the latest earnings report caught analysts off guard and shifted the outlook in a meaningful way.
